CMS takes a stronger interest in off-label device uses
This article was originally published in Clinica
Executive Summary
Medicare rarely ventures into the tricky area of off-label use, preferring to leave such questions up to physicians. But in June, the agency will ask its coverage advisory group to discuss the evidence surrounding transmyocardial revascularisation (TMR), an ablative treatment for the crushing pain of angina.